Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.

PRESS RELEASE

JERUSALEM

--(BUSINESS WIRE)--Jun. 19, 2015--

Teva Pharmaceutical Industries Ltd.

(NYSE and TASE: TEVA) today announced that it has completed the purchase of 4.61 percent of all outstanding shares of

Mylan N.V.

(NASDAQ: MYL), which will enable Teva to commence proceedings before the Dutch Enterprise Chamber, should it become necessary.

Teva has advised Stichting Preferred Shares Mylan that if the Mylan Extraordinary General Meeting (“EGM”) on the

Perrigo

transaction is held no later than

August 31, 2015

, Teva will limit its aggregate shareholding in Mylan prior to the EGM to less than 5 percent of the outstanding shares of Mylan.

Barclays

and

Greenhill & Co.

are serving as financial advisors to Teva.

Sullivan & Cromwell LLP

is serving as legal counsel to Teva, with

De Brauw Blackstone Westbroek N.V.

acting as legal advisor in

the Netherlands

.